MA52365A - Composés et leurs utilisations - Google Patents
Composés et leurs utilisationsInfo
- Publication number
- MA52365A MA52365A MA052365A MA52365A MA52365A MA 52365 A MA52365 A MA 52365A MA 052365 A MA052365 A MA 052365A MA 52365 A MA52365 A MA 52365A MA 52365 A MA52365 A MA 52365A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662673P | 2018-04-25 | 2018-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52365A true MA52365A (fr) | 2021-03-03 |
Family
ID=68290767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052365A MA52365A (fr) | 2018-04-25 | 2019-04-24 | Composés et leurs utilisations |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10919885B2 (fr) |
| EP (1) | EP3784234A1 (fr) |
| JP (1) | JP2021522253A (fr) |
| CN (1) | CN112566636A (fr) |
| MA (1) | MA52365A (fr) |
| WO (1) | WO2019209962A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| EP3566055B1 (fr) | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Inhibiteurs de la scd pour le traitement de troubles neurologiques |
| CA3083000A1 (fr) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Composes et utilisations de ces composes |
| WO2019183587A1 (fr) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Composés et leurs utilisations |
| WO2019195810A2 (fr) | 2018-04-06 | 2019-10-10 | Praxis Biotech LLC | Inhibiteurs d'atf6 et leurs utilisations |
| WO2020154571A1 (fr) | 2019-01-24 | 2020-07-30 | Yumanity Therapeutics, Inc. | Composés et leurs utilisations |
| EP4041727A1 (fr) * | 2019-10-09 | 2022-08-17 | Praxis Biotech LLC | Modulateurs atf6 et leurs utilisations |
| US20230028584A1 (en) * | 2019-10-09 | 2023-01-26 | Praxis Biotech LLC | Atf6 modulators and uses thereof |
| US20220406429A1 (en) * | 2019-11-04 | 2022-12-22 | The Regents Of The University Of California | Artificial Intelligence Enabled Control of Hemodynamics in Surgery Patients |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CA3190277A1 (fr) | 2020-09-03 | 2022-03-10 | Joerg Benz | Composes heterocycliques |
| CN117295726A (zh) * | 2021-04-23 | 2023-12-26 | 豪夫迈·罗氏有限公司 | 杂环化合物 |
| CA3219022A1 (fr) * | 2021-05-21 | 2022-11-24 | Barbara Nave | Utilisation de composes d'ethynylpyridine en tant qu'inhibiteurs de nitrification |
| PL4514782T3 (pl) | 2022-05-19 | 2026-02-23 | Astrazeneca Ab | Związki amidoheteroaromatyczne przydatne w leczeniu chorób wątroby |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7074809B2 (en) | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
| JP4958560B2 (ja) | 2003-12-24 | 2012-06-20 | プロシディオン・リミテッド | Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体 |
| US8008302B2 (en) | 2004-07-26 | 2011-08-30 | Merck Serono Sa | N-hydroxyamide derivatives and use thereof |
| BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
| AU2005286647A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| CA2610196A1 (fr) | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd. | Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| JP2009539884A (ja) | 2006-06-12 | 2009-11-19 | メルク フロスト カナダ リミテツド | ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしてのアゼチジン誘導体 |
| WO2008074835A1 (fr) * | 2006-12-20 | 2008-06-26 | Novartis Ag | Composés organiques |
| BRPI0817211A2 (pt) | 2007-09-20 | 2017-05-16 | Irm Llc | composto composições como moduladores da atividade de gpr119 |
| GB0722077D0 (en) | 2007-11-09 | 2007-12-19 | Smithkline Beecham Corp | Compounds |
| WO2009086303A2 (fr) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
| RU2010142937A (ru) | 2008-03-20 | 2012-04-27 | Форест Лабораториес Холдингс Лимитед (Bm) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| WO2010022055A2 (fr) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibiteurs de canaux sodiques sensibles au potentiel |
| WO2010039186A2 (fr) | 2008-09-23 | 2010-04-08 | Renovis, Inc. | Composés utiles en tant que modulateurs de la faah et leurs utilisations |
| US20120010186A1 (en) | 2009-03-23 | 2012-01-12 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| PL2516425T3 (pl) | 2009-12-23 | 2016-03-31 | Jasco Pharmaceuticals Llc | Inhibitory kinaz aminopirydynowych |
| JP2014525450A (ja) | 2011-09-01 | 2014-09-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ｃ−Ｋｉｔキナーゼ阻害剤としての化合物および組成物 |
| US9358250B2 (en) | 2011-10-15 | 2016-06-07 | Genentech, Inc. | Methods of using SCD1 antagonists |
| WO2013130625A1 (fr) | 2012-02-27 | 2013-09-06 | Basil Rigas | Dérivés de phospho-ester et leurs utilisations |
| EA201500399A1 (ru) | 2012-10-10 | 2015-09-30 | Актелион Фармасьютиклз Лтд. | Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона |
| CN107249583B (zh) * | 2015-02-09 | 2021-05-07 | 国立大学法人冈山大学 | 乳酸脱氢酶抑制剂以及含有该抑制剂的抗癫痫剂 |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
-
2019
- 2019-04-24 JP JP2020559520A patent/JP2021522253A/ja active Pending
- 2019-04-24 US US16/393,183 patent/US10919885B2/en active Active
- 2019-04-24 CN CN201980042740.2A patent/CN112566636A/zh active Pending
- 2019-04-24 MA MA052365A patent/MA52365A/fr unknown
- 2019-04-24 EP EP19792116.6A patent/EP3784234A1/fr not_active Withdrawn
- 2019-04-24 WO PCT/US2019/028928 patent/WO2019209962A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20190330198A1 (en) | 2019-10-31 |
| EP3784234A1 (fr) | 2021-03-03 |
| CN112566636A (zh) | 2021-03-26 |
| US10919885B2 (en) | 2021-02-16 |
| WO2019209962A1 (fr) | 2019-10-31 |
| WO2019209962A8 (fr) | 2020-04-09 |
| JP2021522253A (ja) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3917529A4 (fr) | Composés et leurs utilisations | |
| EP3917527A4 (fr) | Composés et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA52365A (fr) | Composés et leurs utilisations | |
| EP3694861A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3768269A4 (fr) | Composés et leurs utilisations | |
| MA55385A (fr) | Composés et leurs utilisations | |
| EP3849983A4 (fr) | Composés de triazolo-pyrimidine et leurs utilisations | |
| EP3787607C0 (fr) | Compositions de caroténoïdes et leurs utilisations | |
| EP3810182A4 (fr) | Néoantigènes et leurs utilisations | |
| EP3337486A4 (fr) | Composés deutérés et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3649142A4 (fr) | Composés comprenant un lieur clivable et leurs utilisations | |
| MA43205A (fr) | Composés pyy sélectifs et leurs utilisations | |
| EP3790883A4 (fr) | Composés hétéroaryles et leurs utilisations | |
| MA50173A (fr) | Composés activateurs de bisamide sarcomère et leurs utilisations | |
| EP3902530A4 (fr) | Nanovaccins polymères et leurs utilisations | |
| EP3880194A4 (fr) | Composés deutérés, compositions et utilisations | |
| EP4093768A4 (fr) | Constructions cal-t et leurs utilisations | |
| EP3838900A4 (fr) | Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées | |
| EP3846807A4 (fr) | Composés d'imidazoquinoléine et leurs utilisations | |
| EP3853216A4 (fr) | Composés substitués par pyridinyle et leurs utilisations | |
| MA54829A (fr) | Composés et leurs utilisations | |
| MA48956A (fr) | Composés mic-1 et utilisations associées | |
| EP3856741A4 (fr) | Composés polymorphes et leurs utilisations |